FAKTOR-OPTIONSSCHEIN - NOVO-NORDISK B | Market Closed - Deutsche Boerse AG 20:49:19 28/06/2024 BST | ||
| 37.57 EUR | -1.29% |
|
| Current month | +15.39% | ||
| 1 month | +17.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 37.57 | -1.29% |
| 27/06/24 | 38.06 | +0.03% |
| 26/06/24 | 38.05 | -3.08% |
| 25/06/24 | 39.26 | +6.17% |
| 24/06/24 | 36.98 | -0.30% |
Delayed Quote Deutsche Boerse AG
Last update June 28, 2024 at 08:49 pm
More quotesStatic data
| Product type | Exotic Products |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | 
Société Générale
|
| WKN | SQ7YJQ |
| ISIN | DE000SQ7YJQ1 |
| Date issued | 16/01/2023 |
| Strike | 911.9 kr |
| Maturity | Unlimited |
| Parity | 1 : 1 |
| Emission price | 10.06 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 40 € |
|---|---|
| Lowest since issue | 9.09 € |
| Spread | 0.68 € |
| Spread % | 1.79% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
1,006
DKK
Average target price
949.7
DKK
Spread / Average Target
-5.56%
- Stock Market
- Certificates
- Certificat
